Professor James Rondinelli collaborated with IBM to help turn simulations into potential practical chip designs.
Key market opportunities in oncology biosimilars include leveraging AI for streamlined clinical trials and precision medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results